Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6. As per data from Benzinga Pro, the Wall Street estimates sales of $13.7 billion, with adjusted EPS of $4.94.

In January, just before the JP Morgan healthcare conference, Eli Lilly announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.50 billion.

The company’s expected 2024 revenue is $400 million, or about 3%, below the guidance range issued during the third-quarter earnings. The guidance includes approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound.

Also Read: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Analysts are tracking Eli Lilly’s expected increase in sales and profit in the first full quarter, during which its weight-loss drugs ceased to be in shortage.

In October 2024, the FDA determined that Eli Lilly’s tirzepatide injection shortage had been resolved.

The U.S. pharma giant reported third-quarter revenue of $11.44 billion, up 20% year over year, but it missed the consensus of $12.10 billion. Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago.

Sales of Verzenio (a breast cancer drug) increased 32% to $1.37 billion, and sales of diabetes drug Jardiance fell 2% to $686.4 million.

Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to $1.30 billion.

Rival Novo Nordisk A/S (NYSE:NVO) stock is trading higher. On Wednesday, the company reported sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (79.73 billion Danish Kroner).

GLP-1 diabetes sales increased by 12%, and Obesity care sales increased by 91%.

Ozempic sales increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled to 19.87 billion Danish kroner.

According to Reuters, investors and analysts expect Eli Lilly to outline its strategy for promoting Zepbound this year as it aims to compete with Wegovy, a more established drug.

Zepbound holds a little over 50% of the market, according to IQVIA data cited by an analyst. Eli Lilly began advertising the drug in November.

Price Action: LLY stock is up 2.19% at $843.59 at the last check on Wednesday.

Read Next:

• Embraer Lands Record $7 Billion Flexjet Order, Stock Jumps

Image by Mohammed_Al_Ali via Shutterstock